Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agendia, Inc.

Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
From Agendia, Inc.
Via Business Wire
Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit
From Agendia, Inc.
Via Business Wire
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
From Agendia, Inc.
Via Business Wire
Agendia Co-Founder Prof. Dr. Laura van 't Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
From Agendia, Inc.
Via Business Wire
Agendia's FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
From Agendia, Inc.
Via Business Wire
Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays
From Agendia, Inc.
Via Business Wire
Agendia Announces Publication of Utility of MammaPrint® in Prediction of Extended Endocrine Therapy in Journal of Clinical Oncology
From Agendia, Inc.
Via Business Wire
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO
From Agendia, Inc.
Via Business Wire
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
From Agendia, Inc.
Via Business Wire
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
From Agendia, Inc.
Via Business Wire
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
From Agendia, Inc.
Via Business Wire
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
From Agendia, Inc.
Via Business Wire
Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors
From Agendia, Inc.
Via Business Wire
Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
From Agendia, Inc.
Via Business Wire
Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
From Agendia, Inc.
Via Business Wire
Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
From Agendia, Inc.
Via Business Wire
Updated NCCN® Guidelines Recognize MammaPrint® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
From Agendia, Inc.
Via Business Wire
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
From Agendia, Inc.
Via Business Wire
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
From Agendia, Inc.
Via Business Wire
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
From Agendia, Inc.
Via Business Wire
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
From Agendia, Inc.
Via Business Wire
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
From Agendia, Inc.
Via Business Wire
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
From Agendia, Inc.
Via Business Wire
Agendia Demonstrates Accessibility and Affordability of MammaPrint® and BluePrint® in Europe at ESMO Breast Cancer 2022
From Agendia, Inc.
Via Business Wire
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
From Agendia, Inc.
Via Business Wire
Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy
From Agendia, Inc.
Via Business Wire
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
From Agendia, Inc.
Via Business Wire
Agendia to Provide First Digital MammaPrint Capability to Brazil
From Agendia, Inc.
Via Business Wire
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
From Agendia, Inc.
Via Business Wire
Tickers ILMN
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
From Agendia, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.